Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ. Schuurhuis GJ, et al. Among authors: hourigan cs. Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12. Blood. 2018. PMID: 29330221 Free PMC article. Review.
Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years.
Webster JA, Reed M, Tsai HL, Ambinder A, Jain T, Dezern AE, Levis MJ, Showel MM, Prince GT, Hourigan CS, Gladstone DE, Bolanos-Meade J, Gondek LP, Ghiaur G, Dalton WB, Paul S, Fuchs EJ, Gocke CB, Ali SA, Huff CA, Borrello IM, Swinnen L, Wagner-Johnston N, Ambinder RF, Luznik L, Gojo I, Smith BD, Varadhan R, Jones RJ, Imus PH. Webster JA, et al. Among authors: hourigan cs. Transplant Cell Ther. 2023 Mar;29(3):182.e1-182.e8. doi: 10.1016/j.jtct.2022.12.018. Epub 2022 Dec 29. Transplant Cell Ther. 2023. PMID: 36587740 Free PMC article.
Minimal residual disease in acute myeloid leukaemia.
Hourigan CS, Karp JE. Hourigan CS, et al. Nat Rev Clin Oncol. 2013 Aug;10(8):460-71. doi: 10.1038/nrclinonc.2013.100. Epub 2013 Jun 25. Nat Rev Clin Oncol. 2013. PMID: 23799371 Free PMC article. Review.
Next generation MRD.
Hourigan CS. Hourigan CS. Biol Blood Marrow Transplant. 2014 Sep;20(9):1259-60. doi: 10.1016/j.bbmt.2014.07.002. Epub 2014 Jul 10. Biol Blood Marrow Transplant. 2014. PMID: 25016196 Free PMC article. No abstract available.
A multigene array for measurable residual disease detection in AML patients undergoing SCT.
Goswami M, McGowan KS, Lu K, Jain N, Candia J, Hensel NF, Tang J, Calvo KR, Battiwalla M, Barrett AJ, Hourigan CS. Goswami M, et al. Among authors: hourigan cs. Bone Marrow Transplant. 2015 May;50(5):642-51. doi: 10.1038/bmt.2014.326. Epub 2015 Feb 9. Bone Marrow Transplant. 2015. PMID: 25665046 Free PMC article. Clinical Trial.
Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP, Mannis GN, Wood BL, Radich JP, Hwang J, Ramos NR, Andreadis C, Damon L, Logan AC, Martin TG, Hourigan CS. Mulé MP, et al. Among authors: hourigan cs. Biol Blood Marrow Transplant. 2016 Nov;22(11):1974-1982. doi: 10.1016/j.bbmt.2016.08.014. Epub 2016 Aug 17. Biol Blood Marrow Transplant. 2016. PMID: 27544285 Free PMC article.
137 results